In the first quarter of fiscal year 2026, Medtronic saw growth in its overall revenue and neuroscience portfolio, according to financial results posted Aug. 19.
Five things to know:
1. Total revenue reached $8.6 billion, an increase of 8.4% year over year.
2. Medtronic’s neuroscience portfolio saw quarterly gains of 4.3% with $2.4 billion.
3. The cranial and spinal technologies segment within neuroscience saw a 5.5% increase year over year with $1.2 billion. Neuromodulation sales grew 10.2%, and specialty therapies revenue decreased 1.5%.
4. Medtronic’s U.S. sales increased 3.5% year over year with $4.2 billion. Global sales were $4.4 billion, a 6.1% increase.
5. The company saw net income of $1 billion and expects fiscal year 2026 revenue to grow 6.5% to 6.8% compared to fiscal year 2025.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
